Yip TCF, et al. - In a retrospective analysis of 29,350 patients with chronic hepatitis B virus (HBV) infection in China, researchers contrasted the impacts of tenofovir disoproxil fumarate (TDF) vs entecavir on hepatocellular carcinoma (HCC) risk. They conducted a retrospective study of consecutive adults with chronic HBV infection who were initially treated with entecavir or TDF from January 2008 through June 2018, for at least six months. Excluded were patients who had cancers or liver transplantation before or within the first 6 months of treatment. Data were analyzed from 29,350 individuals (mean age, 52.9 ± 13.2 years; 18,685 male (63.7%); 1309 were first treated with TDF (4.5%) and 28,041 were first treated with entecavir (95.5%). Over a median follow-up time of 3.6 years, treatment with TDF was linked to a lower risk of HCC than treatment with entecavir.